Source: Annual Congress 2006 - Drug-induced lung injury – new aspects



Rating:

Share or cite this content

Citations should be made in the following way:
A. Polito (Baltimore, United States of America). Lung disease induced by novel chemotherapeutic agents and biomolecules. Annual Congress 2006 - Drug-induced lung injury – new aspects

Member's Comments

No comment yet.

Related content which might interest you: The loss of pulmonary barrier function as a result of application of anticancer agents paclitaxel, 2-methoxyestradiol, and their combination Source: Annual Congress 2010 - Determinants of acute lung injury and fibrosis Year: 2010 Dynamic monitoring of plasma DAMP proteins during various anticancer agents in advanced lung cancer patients Source: Virtual Congress 2020 – Molecular alterations and immunology in lung cancer Year: 2020 Comparative study of therapeutic effects of combination chemotherapy including various doses of clarithromycin for pulmonary Mycobacterium avium complex disease Source: Annual Congress 2010 - Nontuberculous mycobacterial infections and tuberculosis Year: 2010 Drug-induced lung disease Source: Respipedia Article Year: 2017 Drug-induced infiltrative lung disease Source: Eur Respir J 2001; 18: 93S-100S Year: 2001 Lung disease induced by newer therapies for lung cancer: an update Source: Annual Congress 2006 - Drug-induced lung injury – new aspects Year: 2006 Late Breaking Abstract - The outcome of COVID-19 in interstitial lung disease patients treated with anti-inflammatory drugs and antiviral drugs Source: Virtual Congress 2021 – Prognostic markers of disease progression in non-idiopathic pulmonary fibrosis interstitial lung diseases Year: 2021 Predictive role of MMP-2 genetic variants on severe hematologic toxicity of NSCLC patients treated with first-line, platinum-based chemotherapy Source: Annual Congress 2011 - Genetics of airway diseases and treatment Year: 2011 Immunosuppressive therapy after human lung transplantation Source: ISSN=1025-448x, ISBN=1-904097-29-4, page=105 Year: 2003 Interstitial lung disease induced by exogenous agents: factors governing susceptibility Source: Eur Respir J 2001; 18: 30S-42S Year: 2001 Late Breaking Abstract - Anti-inflammatory activity of novel transtilbene sulfonamide analogues as potential novel therapeutic agents for inflammatory lung disease Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies Year: 2019 Immunosuppressive therapy after human lung transplantation Source: Eur Respir J 2004; 23: 159-171 Year: 2004 The clinical characteristics and treatment responses of tuberculosis in patients with malignancy on anti-cancer chemotherapy Source: Eur Respir J 2005; 26: Suppl. 49, 690s Year: 2005 The side-effects of TB therapy: myth and reality Source: Annual Congress 2005 - PG10 - The management of tuberculosis: tradition and novelties Year: 2005 Sulphasalazine and lung toxicity Source: Eur Respir J 2002; 19: 756-764 Year: 2002 How to use new immunosuppressive drugs in lung transplantation Source: Annual Congress 2006 - MP5 – How to use new immunosuppressive drugs in lung transplantation Year: 2006 The role of somatostatin analogues in combination to antineoplastic agents in the treatment of SCLC patients (preliminary findings) Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009 A possible role of intracellular calcium in the development of anti-cancer therapy -resistance in lung cancer cells Source: Eur Respir J 2006; 28: Suppl. 50, 853s Year: 2006 Development of a new calcilytic for the treatment of inflammatory lung disease Source: International Congress 2018 – Basic pharmacology Year: 2018 Immunotherapy and pulmonary toxicities: can concomitant immune-checkpoint inhibitors with radiotherapy increase the risk of radiation pneumonitis? Source: Eur Respir J, 51 (1) 1701737; 10.1183/13993003.01737-2017 Year: 2018